Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Croatia has been experiencing steady growth in recent years.
Customer preferences: Croatian customers have shown a preference for generic drugs over branded ones due to their lower cost. This has led to an increase in the production and consumption of generic drugs in the country. Additionally, there has been a growing demand for over-the-counter (OTC) drugs as consumers become more health-conscious and seek to self-medicate for minor ailments.
Trends in the market: One notable trend in the Croatian Pharmaceuticals market is the increasing focus on research and development (R&D) to produce new and innovative drugs. This has been driven by government incentives and partnerships with international pharmaceutical companies. Another trend is the growing use of e-commerce platforms for the sale and distribution of pharmaceutical products, which has made it easier for consumers to access a wider range of products.
Local special circumstances: Croatia's accession to the European Union in 2013 has had a significant impact on the Pharmaceuticals market. The country's membership has led to increased regulatory harmonization and alignment with EU standards, which has made it easier for international pharmaceutical companies to operate in the country. Additionally, the country's aging population and high prevalence of chronic diseases have created a growing demand for pharmaceutical products.
Underlying macroeconomic factors: The Croatian economy has been recovering from a recession in recent years, which has led to increased consumer spending power and a growing middle class. This has contributed to the growth of the Pharmaceuticals market as consumers are able to afford more expensive drugs. Additionally, the government's focus on healthcare reforms and investments in the sector have created a favorable environment for pharmaceutical companies to operate in.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)